Previous 10 | Next 10 |
home / stock / jnj / jnj articles
A jury has ruled that Johnson & Johnson (NYSE:JNJ) must pay $260 million to an Oregon woman who claims to have developed mesothelioma from usin...
Monday, Johnson & Johnson (NYSE:JNJ) announced longer-term data from Phase 1/2 MajesTEC-1 study of Tecvayli (teclistamab-cqyv) showing deep and...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap...
Wednesday, Johnson & Johnson (NYSE:JNJ) announced topline results from Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of sel...
The mass retirement of the boomer generation has been anticipated as one of the most impactful economic events of the 21st century. Economists are ...
J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indicat...
A group of cancer victims has reportedly filed a lawsuit against Johnson & Johnson (NYSE:JNJ), accusing the healthcare gian...
Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the Vanguard Health Care ETF (ARCA:VHT), a p...
In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze compani...
News, Short Squeeze, Breakout and More Instantly...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with tr...
2024-07-18 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 05:40:00 ET On July 17, Johnson & Johnson (NYSE: JNJ) announced second-quarter results that gave investors a lot to look forward to. Integration of newly acquired medical technology plus upcoming expansions of patent-protected medicines will help push the healthcare c...